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The impact of COVID-19 is well documented, with over sixteen million people infected and 665,000 deaths [1]. With any infection it is necessary to consider countermeasures which can improve im-mune functioning and the immunological response to vaccination. Our bodies are host to large numbers of bacteria which colonise the skin and the digestive system. These organisms are referred to as microbiota and interest here lies in the gut microbiota. These show large individual variation [2], which may plausibly explain differences in susceptibility to and severity of disease. An abnor-mal gut microbiota is referred to as gut dysbiosis, and this has been shown to be a risk factor for disease. For example, hypertension is linked to gut dysbiosis [3], as is coronary heart disease [4]. Similar-ly, patients with both Type 1 [5] and Type 2 [6] diabetes show signs of gut dysbiosis. Susceptibility to, and the severity of COVID-19 has been shown to be associated with the same diseases that lead to gut dysbiosis. This suggests that one plausible method of prevent-
ing and managing COVID-19 might be by beneficial changes in the gut microbiota. This could involve the use of probiotics or possibly 
prebiotics that lead to positive changes in gut flora.Probiotic bacteria compete with pathogenic bacteria for nutri-ents and also interact with the epithelium of the gut and immune tissues in the digestive system [7]. These effects may be due to chemical changes or direct contact between cells. There is evi-dence that some probiotics can enhance phagocytosis and natural killer cell activity [8]. There is also evidence that probiotics may improve the immunological responses following vaccination [9]. The Handbook of COVID-19 Prevention and Treatment [10] de-scribes COVID-19 patients who have had abdominal pain and diar-rhoea which may be caused by infection of the intestinal mucosa. The dysbiosis seen in these patients [11] suggests that probiotics 
might be beneficial. However, this conclusion is based on the ex-
isting literature rather than evidence from clinical trials [12]. The 
gut bacteria, particularly lactobacilli and bifidobacteria, do seem to also reduce the incidence and severity of upper respiratory tract infections [13]. This, again, suggests that they may have some ef-
ficacy in the prophylactic and therapeutic treatment of COVID-19. This view is supported by results from a recent study from China [14]. In this Chinese study, the researchers isolated 20 proteins as-sociated with disease severity of COVID-19 patients. The proteins were then used to create a risk score that could predict the severity of the disease. They then correlated the risk scores with the qual-ity of the gut microbiome as analysed from faecal samples. The re-sults showed that a poor microbiome score was a better predictor of symptom severity that traditional indicators of health (e.g. body mass index, blood pressure and age). The results of this study have to be treated with caution due to the small number of COVID-19 patients. Evidence from Italy [15] also suggests that probiotics, combined 
with other compounds, may have benefits for COVID-19 patients. The study started with the observation of frequent gastrointesti-nal problems in COVID-19 patients. Probiotic administration led to a remission of diarrhoea and other gastrointestinal symptoms in nearly all of the group. In contrast, half of those not given probi-otics showed a persistence of the symptoms. The removal of the digestive tract symptoms is not unexpected. However, those given the probiotics also showed an eight-fold lower risk of developing respiratory failure compared to those not given probiotics. The impact of gut microbiota on lung function is an established con-cept, namely the “gut-lung axis” [16]. Patients with gastrointesti-nal disorders often have a higher incidence of pulmonary disease, 
which might reflect gut-derived metabolites priming myeloid cells 
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in the bone marrow, which then migrate to the lungs and change 
inflammation. Therefore, while the results of the Italian study are plausible, replication is required to examine whether effects gen-eralise to a more diverse sample of patients and other probiotic formulations. Other authors [17] have been more specific about the probiotic regime necessary to combat COVID-19. They argue that a preventative dose would be one capsule with at least 109 Colony 
Forming Units of Lactobacillus or Bifidobacterium species during a meal [18,19]. Those with COVID-19 should take two such capsules three times daily. If the patient is on invasive mechanical ventila-tion they should be given two opened capsules three times a day by enteral feeding.The above account suggests that the gut microbiota may play a major role in COVID-19. This suggests that probiotics may be im-portant, but one should also remember that a healthy diet, rather than supplements, plays a role in maintaining a healthy gut micro-biota. The literature contains many examples of clinical trials that 
have investigated beneficial effects of probiotics. In the case of CO-VID-19, such trials will initially aim to demonstrate that probiotics lead to a reduced risk of developing the disease. It is also possible that they may reduce symptom severity, and even, as in the Ital-ian study, increase the likelihood of remission of gastrointestinal symptoms present in those with COVID-19. Overall, one can now suggest that nutritional studies should be part of the prevention and management of COVID-19. It is also important to point out that changing the gut microbiota is one of many approaches to treating COVID-19. Indeed, even within the area of nutrition, there are other approaches which may turn out to be extremely useful [13]. For example, a severe infection of the respiratory epithelium leads to ARDS, which is characterised by a cytokine storm. This is often ob-served in severe cases of COVID-19. Studies of ARDS in the context of other diseases has shown that the cytokine storm can be con-trolled by the n-3 fatty acids EPA and DHA. This suggests further interventions and the need for a holistic approach to the preven-tion and management of COVID-19.
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